InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,783.20
(
0.68%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.94
(
0.00%
)
Bitcoin
68,181.70
(
-0.26%
)
Post# of 661849
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mark

Send PM Follow Ignore
Followers 1387
Posts 74819
Boards Moderated 1
Alias Born 08/20/2007

Mark

Member Level

Re: AugustaFriends post# 587825

Thursday, 04/20/2023 7:36:40 AM

Thursday, April 20, 2023 7:36:40 AM

Post# of 661849
They had two price targets published late last night and this morning:

EF Hutton analyst Michael King reiterates Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $6.7 price target.

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $22 to $17.

Guessing this is why it got volume early....
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up